206 related articles for article (PubMed ID: 20926944)
1. Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.
Li YY; Chang JW; Liu YC; Wang CH; Chang HJ; Tsai MC; Su SP; Yeh KY
Anticancer Drugs; 2011 Jan; 22(1):89-98. PubMed ID: 20926944
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners.
Okamoto S; Kawamura K; Li Q; Yamanaka M; Yang S; Fukamachi T; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M
J Thorac Oncol; 2012 May; 7(5):873-82. PubMed ID: 22481236
[TBL] [Abstract][Full Text] [Related]
4. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
[TBL] [Abstract][Full Text] [Related]
5. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F.
Leone G; DeGregori J; Sears R; Jakoi L; Nevins JR
Nature; 1997 May; 387(6631):422-6. PubMed ID: 9163430
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid induces S-phase arrest via a DNA damage response in normal human oral keratinocytes.
Ohnuki H; Izumi K; Terada M; Saito T; Kato H; Suzuki A; Kawano Y; Nozawa-Inoue K; Takagi R; Maeda T
Arch Oral Biol; 2012 Jul; 57(7):906-17. PubMed ID: 22172403
[TBL] [Abstract][Full Text] [Related]
7. Regulation of expression and activity of distinct pRB, E2F, D-type cyclin, and CKI family members during terminal differentiation of P19 cells.
Gill RM; Slack R; Kiess M; Hamel PA
Exp Cell Res; 1998 Oct; 244(1):157-70. PubMed ID: 9770359
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells.
Zhu WY; Jones CS; Kiss A; Matsukuma K; Amin S; De Luca LM
Exp Cell Res; 1997 Aug; 234(2):293-9. PubMed ID: 9260897
[TBL] [Abstract][Full Text] [Related]
9. Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells.
Fribourg AF; Knudsen KE; Strobeck MW; Lindhorst CM; Knudsen ES
Cell Growth Differ; 2000 Jul; 11(7):361-72. PubMed ID: 10939590
[TBL] [Abstract][Full Text] [Related]
10. p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
Kuroda J; Kimura S; Segawa H; Sato K; Matsumoto S; Nogawa M; Yuasa T; Kobayashi Y; Yoshikawa T; Ottmann OG; Maekawa T
Cancer Sci; 2004 Feb; 95(2):186-92. PubMed ID: 14965371
[TBL] [Abstract][Full Text] [Related]
11. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes.
Flink IL; Oana S; Maitra N; Bahl JJ; Morkin E
J Mol Cell Cardiol; 1998 Mar; 30(3):563-78. PubMed ID: 9515032
[TBL] [Abstract][Full Text] [Related]
12. Anticancer effects of zoledronic acid against human osteosarcoma cells.
Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
[TBL] [Abstract][Full Text] [Related]
13. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation.
Albino AP; Juan G; Traganos F; Reinhart L; Connolly J; Rose DP; Darzynkiewicz Z
Cancer Res; 2000 Aug; 60(15):4139-45. PubMed ID: 10945621
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the cell cycle at the G2/M boundary in metastatic melanoma cells by 12-O-tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc2 kinase activity.
Arita Y; Buffolino P; Coppock DL
Exp Cell Res; 1998 Aug; 242(2):381-90. PubMed ID: 9683525
[TBL] [Abstract][Full Text] [Related]
16. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Cai D; Byth KF; Shapiro GI
Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
[TBL] [Abstract][Full Text] [Related]
17. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T
Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996
[TBL] [Abstract][Full Text] [Related]
19. p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest.
Green SL; Freiberg RA; Giaccia AJ
Mol Cell Biol; 2001 Feb; 21(4):1196-206. PubMed ID: 11158306
[TBL] [Abstract][Full Text] [Related]
20. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.
Marra M; Santini D; Meo G; Vincenzi B; Zappavigna S; Baldi A; Rosolowski M; Tonini G; Loeffler M; Lupu R; Addeo SR; Abbruzzese A; Budillon A; Caraglia M
Int J Cancer; 2009 Nov; 125(9):2004-13. PubMed ID: 19530242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
